Viatris Named to Fortune's World's Best Workplaces™ List for Second Consecutive Year

(NASDAQ:VTRS) Viatris Inc. announced that it has been named to Fortune's World's Best Workplaces™ list for the second consecutive year. The recognition is based on Great Place To Work's (GPTW) assessment process, which includes confidential employee feedback. This year's evaluation drew on more than 9 million survey responses representing more than 23 million employees worldwide. The list recognizes 25 global organizations. Lara Ramsburg, Chief People and Corporate Affairs Officer at Viatris, stated that the recognition reflects the experiences of colleagues around the world and the culture being built at the company. To be considered for the list, companies must be GPTW Certified™ organizations and must have appeared on at least five Best Workplaces lists in Asia, Europe, Latin America, Africa, North America, or Australia during 2025 or early 2026. Companies must also have at least 5,000 employees worldwide. The assessment evaluates organizations on their efforts to create great workplaces and positively impact people and communities across multiple countries. Michael C. Bush, CEO of Great Place To Work, emphasized the importance of trust in organizations. Viatris' recognition adds to other honors, including Forbes' list of World's Best Employers 2026, TIME's World's Most Impactful Companies 2026, TIME's World's Most Sustainable Companies 2026, Newsweek's World's Greenest Companies 2026, Business Insider's America's Most Innovative Businesses 2027, and 3BL's 100 Best Corporate Citizens 2026. Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai, and Hyderabad, India. The company has a broad portfolio that spans generics, value-added medicines, established brands, and innovative medicines. The Great Place To Work Trust Index™ Survey is used for consideration on the list. The methodology for the World's Best Workplaces list includes gathering and analyzing more than 9 million confidential survey responses, representing the experiences of 23 million employees worldwide at Great Place To Work Certified organizations.

Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.

(NASDAQ:VTRS) Viatris Inc. announced that its wholly owned subsidiary, Peach Purchaser Sub Inc., has commenced a tender offer to purchase all issued and outstanding shares of common stock, par value $0.001 per share, of Pacira BioSciences, Inc. (NASDAQ:PCRX) for $36.50 per share in cash, net of applicable withholding taxes and without interest. The offer is made pursuant to the Agreement and Plan of Merger dated October 8, 2026, among Viatris, Purchaser, and Pacira. Following the consummation of the offer, Purchaser will be merged with and into Pacira, with Pacira continuing as the surviving corporation and becoming a wholly owned subsidiary of Viatris. Each share issued and outstanding immediately prior to the effective time of the merger will be converted into the right to receive $36.50 per share in cash, net of applicable withholding taxes and without interest. The merger will be governed by Section 251(h) of the Delaware General Corporation Law and does not require a vote of Pacira's stockholders. Purchaser may not provide any subsequent offering period for the offer without the prior written consent of Pacira. Pacira's board of directors has published a Solicitation/Recommendation Statement on Schedule 14D-9 and filed it with the SEC on October 30, 2026, which includes the unanimous recommendation that Pacira's stockholders accept the offer and tender their shares. The offer and withdrawal rights will expire one minute following 11:59 p.m. Eastern Time on November 16, 2026, unless extended or earlier terminated. Shares tendered may be withdrawn at any time prior to the expiration date and, if not yet accepted for payment, may also be withdrawn at any time after December 29, 2026. Purchaser will promptly accept for payment and pay for all shares validly tendered and not validly withdrawn as soon as practicable after the offer acceptance time. The obligation to pay for shares is subject to certain conditions, including the Minimum Condition, expiration or termination of the Hart-Scott-Rodino waiting period, and the absence of any legal restraint prohibiting the offer or merger. The Minimum Condition requires that, prior to the expiration date, there have been validly tendered (and not validly withdrawn) a number of shares that, together with shares owned by Purchaser and its affiliates, represents at least one share more than 50% of the total number of shares issued and outstanding at the time of expiration, excluding shares tendered by guaranteed delivery procedures not yet received by the depository. The offer is not subject to a financing condition. Pacira has provided Purchaser with its stockholder list and other information for the purpose of disseminating the offer. The offer documents are available at https://www.shareholdermaterials.com/pcrx2026/.

Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia

(NASDAQ:VTRS) Viatris Inc. announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI® (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults. RYZUMVI is already approved in the United States for the treatment of pharmacologically-induced mydriasis and is the only commercially available FDA-approved product for that indication. This new approval expands RYZUMVI's indications to include presbyopia. Viatris is currently exploring the potential for a partner in the United States to commercialize RYZUMVI for presbyopia. Opus Genetics and Viatris Inc. (through an affiliated entity) are parties to a global licensing agreement for the development of phentolamine ophthalmic solution 0.75%, which grants Viatris exclusive rights to commercialize the product in the United States. Presbyopia is described as the gradual loss of near focusing ability due to aging, typically becoming noticeable in the early to mid-40s, and is a nearly universal condition that can significantly impact daily tasks and productivity. RYZUMVI (phentolamine ophthalmic solution) 0.75% is indicated for the treatment of presbyopia in adults and for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists or parasympatholytic agents in adults and pediatric patients 3 years of age and older. The most common ocular adverse reactions reported in more than 5% of subjects treated for presbyopia were conjunctival hyperemia (21%) and instillation site irritation (16%). For pharmacologically-induced mydriasis, the most common ocular adverse reactions reported in more than 5% of subjects were instillation site discomfort including pain, stinging, and burning (16%) and conjunctival hyperemia (12%). The only non-ocular adverse reaction reported in more than 5% of subjects was dysgeusia (6%). The majority of adverse reactions were mild, transient, and self-resolving. RYZUMVI is not recommended for use in patients with active ocular inflammation such as iritis. Contact lens wearers should remove their lenses prior to instillation of RYZUMVI and wait 10 minutes after dosing before reinserting their contact lenses. Viatris Inc. is headquartered in the United States, with global centers in Pittsburgh, Shanghai, and Hyderabad, India.

U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain

Viatris Inc. (NASDAQ:VTRS) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MR-107A-02 (fast-acting meloxicam), a non-opioid treatment for moderate-to-severe acute pain. The FDA has assigned a PDUFA goal date of Dec. 27, 2026. The NDA is supported by data from two Phase 3 trials involving 579 herniorrhaphy subjects and 410 bunionectomy subjects, where fast-acting meloxicam met primary and secondary endpoints. Acute pain affects more than 80 million individuals in the United States each year, and opioids remain a commonly used treatment option. Viatris is pursuing several value-added medicines, including fast-acting meloxicam, to drive high value products through life cycle optimization. The company is headquartered in the U.S., with global centers in Pittsburgh, Shanghai, China, and Hyderabad, India. Next steps include awaiting the FDA's decision by the PDUFA goal date and continuing to advance value-added medicines in its pipeline.

Viatris Announces Quarterly Dividend

Viatris Inc. (NASDAQ:VTRS) announced that its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on June 17, 2026, to shareholders of record as of the close of business on May 22, 2026. Viatris is a global healthcare company with headquarters in the U.S. and global centers in Pittsburgh, Shanghai, China, and Hyderabad, India. The announcement includes forward-looking statements regarding the dividend and outlines various risks and uncertainties that could affect future results.

Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting

Viatris Inc. (NASDAQ:VTRS) announced that six abstracts on its investigational low-dose estrogen combined hormonal contraceptive (CHC) weekly patch will be presented at the 2026 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting. The presentations include positive results from a previously announced Phase 3 study (NCT05139121) evaluating the efficacy and safety of the patch. The U.S. FDA has accepted for review the New Drug Application (NDA) for this patch under the 505(b)(2) regulatory pathway, with a target action date (PDUFA) of July 30, 2026. The patch is designed for women of childbearing potential with a BMI below 30 kg/m² seeking a non-invasive, reversible birth control option. Viatris also provided an independent educational grant for a related symposium at the meeting.